SRC activity has also been implicated in resistance of ovarian cancer cells to anti-estrogen therapies, and a combination of the SRC inhibitor saracatinib (AZD0530) and fluvestrant resulted in increased cell cycle arrest and decreased survival of ovarian cancer cells [12]. Here, SRC is linked to ovarian cancer.